Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, includin… Read more
Q linea AB (QLINEA) - Total Liabilities
Latest total liabilities as of December 2025: Skr31.66 Million SEK
Based on the latest financial reports, Q linea AB (QLINEA) has total liabilities worth Skr31.66 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Q linea AB - Total Liabilities Trend (2015–2025)
This chart illustrates how Q linea AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Q linea AB Competitors by Total Liabilities
The table below lists competitors of Q linea AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HYUNDAI BIOLAND Co.Ltd
KQ:052260
|
Korea | ₩27.91 Billion |
|
Cell MedX Corp
OTCQB:CMXC
|
USA | $1.02 Million |
|
TMT Steel Public Company Limited
BK:TMT
|
Thailand | ฿5.54 Billion |
|
TAPEX INC
KO:055490
|
Korea | ₩39.20 Billion |
|
LGL Group Inc
NYSE MKT:LGL
|
USA | $1.38 Million |
|
Papirfabrikken Invest A/S
CO:PFINV
|
Denmark | Dkr365.27 Million |
|
SFOODS
HE:SFOODS
|
Finland | €20.90 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Q linea AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 8.66 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Q linea AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Q linea AB (2015–2025)
The table below shows the annual total liabilities of Q linea AB from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr31.66 Million | -81.95% |
| 2024-12-31 | Skr175.45 Million | +314.37% |
| 2023-12-31 | Skr42.34 Million | -7.47% |
| 2022-12-31 | Skr45.76 Million | +27.65% |
| 2021-12-31 | Skr35.84 Million | +11.89% |
| 2020-12-31 | Skr32.03 Million | -4.26% |
| 2019-12-31 | Skr33.46 Million | +30.66% |
| 2018-12-31 | Skr25.61 Million | +51.67% |
| 2017-12-31 | Skr16.89 Million | +100.84% |
| 2016-12-31 | Skr8.41 Million | +51.37% |
| 2015-12-31 | Skr5.55 Million | -- |